Metastatic Porocarcinoma Effectively Managed by Pembrolizumab

Singh, A.; Nguyen, Lam Tung; Everest, Stephanie; Vinogradov, Mikhail

doi:10.7759/cureus.20004

Cited by 8 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunotherapy with pembrolizumab, which is a programmed cell death protein 1 (PD-1) inhibitor, could be a novel effective treatment for metastatic PC. Although cases are few (three cases), two cases with metastatic PC achieved good courses [ 58 , 67 , 75 ]. Lee et al reported the first PC case treated with pembrolizumab (Case #2) [ 58 ].…”

Section: Treatmentsmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and Management of Porocarcinoma

Miyamoto

Yanagi

Maeda

et al. 2022

Cancers

View full text Add to dashboard Cite

Eccrine porocarcinoma, also known as porocarcinoma (PC) and malignant eccrine poroma, is very rare and is known to arise from the cutaneous intraepidermal ducts of the sweat glands. Its etiology is not well understood; however, some studies suggest that PC tumors originate from benign eccrine poroma. Recently, several gene alterations have been reported in PC that can reveal mechanisms of the oncogenic process. Since the clinical and histopathological findings of PC are variable, PC is difficult to diagnose precisely, especially when the histology resembles that of cutaneous squamous cell carcinoma or poroma. Immunohistochemical staining with carcinoembryonic antigen and epithelial membrane antigen may help to distinguish PC from other tumors. The standard treatment for local PC is wide local excision. The prognosis of patients with metastatic PC is poor, with mortality rates of approximately 60–70%. The efficacy of radiation and chemotherapy for metastatic PC is limited; however, immunotherapy with pembrolizumab, a programmed cell death protein 1 inhibitor, could be a promising treatment. This review focuses on the history, pathogenesis, pathological features, diagnosis, and treatment of eccrine porocarcinoma.

show abstract

Section: Treatmentsmentioning

confidence: 99%

“…The tumor has been in remission for 22 months. A case reported by Singh et al has remained in partial remission for 18 months from the administration of pembrolizumab (Case #11) [ 67 ]. As seen above, pembrolizumab may have the potential to become an alternative treatment, or even a primary treatment, for metastatic PC.…”

Section: Treatmentsmentioning

confidence: 99%

Diagnosis and Management of Porocarcinoma

Miyamoto

Yanagi

Maeda

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…One case reported by Lee et al received complete response for 16 months after switching to pembrolizumab (19). The other case reported by Singh et al showed partial remission for 18 months after the administration of pembrolizumab (20). Gupta reported that a patient who developed an eccrine carcinoma demonstrated a durable antitumor response after treatment with pembrolizumab (21).…”

Section: Discussionmentioning

confidence: 95%

“…However, limited cases with immunotherapy have been reported in SGC. Two cases with metastatic porocarcinoma obtained good results after being treated with pembrolizumab, which is a PD-1 inhibitor ( 19 , 20 ). One case reported by Lee et al.…”

Section: Discussionmentioning

confidence: 99%

Case report: Case report and literature review: Treatment of sweat gland carcinoma

2023

View full text Add to dashboard Cite

BackgroundSweat gland carcinoma (SGC) is a rare neoplasm originating from sweat glands. Surgical resection is the first choice for SGC treatment, and there is no consensus on other treatments for advanced SGC.Methods and resultIn this case report, we present a case of a female patient with advanced SGC who received surgery; radiotherapy; multiple lines of chemotherapy, which include docetaxel, nedaplatin, albumin-bound paclitaxel, and pemetrexed; and immunotherapy (camrelizumab). The survival time of this patient is 35 months. MRI tumor monitoring indicated that these treatments slowed the progression of the disease. The effectiveness of chemotherapy, radiotherapy, and immunotherapy should be tested for more patients with SGC in the future.ConclusionAlthough the patient’s tumor was uncontrolled eventually, multiple treatments delayed tumor growth over a period of time, providing ideas for others when choosing regimens.

show abstract

“…Considering that hypermutated tumors are sensitive to immunotherapy, some authors have also evaluated its efficacy in EPC. In that direction, there have been reports of EPCs responding to anti-PD-1 therapy with nivolumab with or without prior anti-EGFR therapy with cetuximab, while some reports have demonstrated tumor response to pembrolizumab following progression to radiochemotherapy [ 30 , 31 , 62 ]. Although current evidence is limited, immunotherapy may represent a promising treatment option for advanced or metastatic EPCs, warranting further investigation.…”

Section: Treatmentmentioning

confidence: 99%

Eccrine Porocarcinoma: A Review of the Literature

et al. 2023

View full text Add to dashboard Cite

Eccrine porocarcinoma (EPC) constitutes a rare malignant adnexal tumor, which accounts for about 0.005–0.01% of all cutaneous malignancies. It may develop de novo or arise from an eccrine poroma, after a latency period of years or even decades. Accumulating data suggest that specific oncogenic drivers and signaling pathways may be implicated in its tumorigenesis, while recent data have demonstrated a high overall mutation rate attributed to UV exposure. Diagnosis may be challenging and should rely on the combination of clinical, dermoscopical, histopathological and immunohistochemical findings. The literature is controversial regarding tumor behavior and prognosis and, therefore, there is no consensus on its surgical management, utility of lymph-node biopsy and further adjuvant or systemic treatment. However, recent advances in tumorigenesis of EPC may aid in the development of novel treatment strategies, which could improve survival of advanced or metastatic disease, such as immunotherapy. This review presents an update of the epidemiology, pathogenesis and clinical presentation of EPC and summarizes current data on diagnostic evaluation and management of this rare cutaneous malignancy.

show abstract

Metastatic Porocarcinoma Effectively Managed by Pembrolizumab

Cited by 8 publications

References 8 publications

Diagnosis and Management of Porocarcinoma

Diagnosis and Management of Porocarcinoma

Case report: Case report and literature review: Treatment of sweat gland carcinoma

Eccrine Porocarcinoma: A Review of the Literature

Contact Info

Product

Resources

About